Trial Profile

A Randomized, Open-Label, Multicenter, Controlled, Pivotal Study To Assess Safety And Efficacy Of Elad In Subjects With Alcohol-Induced Liver Decompensation (AILD)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 26 Oct 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Extracorporeal hepatocyte-based therapy (Primary)
Indications Alcoholic hepatitis; Liver failure
Focus Therapeutic Use
Sponsors Vital Therapies

Most Recent Events

24 Oct 2018 Status changed from active, no longer recruiting to discontinued.
18 Oct 2018 This trial was discontinued in Germany, according to European Clinical Trials Database.
04 Oct 2018 This trial was discontinued in Ireland (end date: 2018-09-14), according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com